← Back to patent-cliff list
LAD-191
Tier C — Watch / tradeLAD-191
Almirall Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Hidradenitis suppurativa, 自身免疫疾病
Regional status
US
Phase I
2022-07-29
EU
Phase II
2025-11-05
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LAD-191?
Approved indications include: Hidradenitis suppurativa, 自身免疫疾病.
When does the LAD-191 patent expire?
No public expiry year is available for LAD-191 yet; this page updates once verified.
How do I get a quote for LAD-191 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30